I do believe we spike on the news of the hold being

New Post Public Reply Private Reply Replies (3) Message Board
Respert24
942
I do believe we spike on the news of the hold being released, I just don't know how high. It could catch enough shorts off guard that the scramble to exit positions jumps it over a buck. Or it doesn't get close to that and only bumps up toward .50.

From there though, it's anyone's guess. I think it's entirely possible to see some really significant increases if we get quick news after the hold about either a partnership with a legit big pharma company or an announcement that a BLA is back in business with a near term possibility of an approval.

As far as a big pharma partner, I'm talking about Gilead or Merck level companies. If they're throwing around possibilities of combining LL eventually with a Keytruda, for instance, that should be quite the catapult for our price. But if it's a partnership with an unknown group with 8 employees we'll see the mechanism fail before the catapult even starts to pull. If they announce that Craig's Biotech & Animal Husbandry LLC has offered a very generous percentage on future sales for US rights I think we'd see the price fall.

In regards to a BLA, I'm not on board with the theory that they're just going to approve us out of the blue within a few weeks under guidance that we complete a phase 4 to shore up any missing information post approval. I think it's more likely that we either complete whatever that trial is first, or that we are allowed to resubmit a BLA, which gives the FDA six months to review and eventually approve. Either result would be fantastic, I just don't think we're going to jump from incomplete BLA that independent auditors say would fail instantly, to shoring up the safety hold and magically getting approval. If it took them two years to answer six questions from the FDA I can't imagine they also were able to complete a new BLA in that timeframe for the patient population they've just recently started to hone in on with the help of the FDA.

So while I like the idea of that reddit poster's 26 days to $35, I think it would take a lot longer than that for all of his predictions to play out. And I don't necessarily agree with all of them anyway. I'm not sold on the idea that Cytodyn moved their manufacturing tech somewhere else. I think the wording of the entire FAQ and letter, and specifically that paragraph where it's mentioned, means they were speaking historically of a significant hurdle that was achieved along the path to where we are now. Not a recent transfer that leads some to think a new partner will be taking that over.

I also don't think that announcing a MASH trial and getting it approved is something that happens quickly. They can announce they've submitted a protocol, but then the FDA will take 60+ days or something to review it and rubber stamp it.

But overall I do think we'll get news of the hold release followed by at least two more important PRs. Funding via a partnership of some kind should be one, and news about why the FDA hosted an ADCOM-style meeting about LL and HIV should be another. And those two or three things should help get us back into a respectable price range measured in dollars versus cents.

Oh, and up almost 4% right out of the gates today?

Somebody...

Must...

Know...

Something...

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Black Friday Doubt Grows: Just 54% Trust Real Deals

Updated Category News Views 127

Do Shoppers Believe in Black Friday Anymore? You'd think by now, retailers would have cracked the code on building trust with their customers. But guess what? A fresh survey from Boston Consulting Group reveals only 54% of consumers buy the whole Black Friday discount story. That's barely more than flipping a coin. Promotion Fatigue: The Trust Buster Funny thing,...

Continue Reading
Young Storytellers Honored: Bridging Cultures Through Journalism

Updated Category News Views 6

Leaders of Tomorrow: Campus News Awards 2026 It's no small feat to look at a room full of young journalists and see the future of how stories will be told. But that's exactly what happened at the Campus News Awards 2026 in Shenzhen. Here, kids from Hong Kong, Macao, Taiwan, and Southeast Asia stood proudly with their certificates, ready to tackle the changing landscape of...

Continue Reading
TSX Surges Amid Earnings Wave and Market Momentum

Updated Category News Views 46

TSX Soars, But What's Driving the Surge? Gotta say, when the TSX leaps over 2% in a single day, it sets the stage for two things: excitement and scrutiny. On a balmy Wednesday, Canada's stock market stood tall at 36,317.67, up 785.39 points. Wall Street joined the dance too, with the Dow kicking up by 1,543.75 points. Good vibes all around — but hang on a minute. You...

Continue Reading
Marini SkinSolutions Wins with Night Zyme Complex

Updated Category News Views 13

Shaking Up the Skincare Scene You don't often see a skincare product snag three prestigious awards in one year, but that's exactly what's unfolding for Marini SkinSolutions. This time, their Night Zyme® Overnight Glass Skin Resurfacing Complex grabbed the 2026 Shop TODAY Ageless Beauty Award. It’s turning heads and not just in beauty aisles but among investors eyeing a...

Continue Reading
Defense Contractors Eye Larger Backlogs Amid Funding Uncertainty

Updated Category News Views 144

Playing Chicken with Federal Deadlines We've got ourselves a situation where defense contractors are juggling bigger backlogs while the clock ticks down to a looming federal funding deadline on December 11. If this sounds like a high-stakes game of chicken, it's because it is. No one knows if Congress will stitch things up before the stopgap funding dries up. Hell, maybe...

Continue Reading
MAURE's Three-Year Mark: Crafting Home Elegance

Updated Category News Views 39

Brooklyn's Gem: MAURE Turns Three Over in Brooklyn, there's a brand bubbling with style called MAURE. Now, we're talking three years strong, surviving the wild bout of the retail scene with a firm two feet planted in home and gifting. The Vision Turned Reality When Maureen Cavalieri, a hospitality veteran since 2009, first tossed this spark into the wind in 2023, it...

Continue Reading
Trimble's Q3 2026: Guidance Update and Record ARR

Updated Category News Views 89

Trimble Smashes Through Q3 Expectations Trimble Inc. (NASDAQ:TRMB) tossed a bit of a curveball by posting Q3 2026 results that sailed past analyst forecasts. We’re talking revenue swelling to $966.8 million, a decent 7% bump from the previous year. Now, for a company riding its 'Connect & Scale' strategy, this serves as a validation of its aggressive scaling ambitions....

Continue Reading
Duolingo Faces Class Action: Investors React Strongly

Updated Category News Views 63

Duolingo's Rough Road: A Lawsuit in Motion Alright, fasten your seatbelts, because we've got a real rollercoaster here with Duolingo (NASDAQ: DUOL). You know, the language-learning app that's been pushing ads like it's going out of style? Well, investors are seeing red—not the kind you want, either. This class action lawsuit looming over them is like an unwelcome...

Continue Reading
Natixis' $100M Student Challenge Mixes Real Stakes

Updated Category News Views 127

Opportunity Knocks for Budding Portfolio Managers Picture this: You're a student, neck-deep in textbooks and theories, and then bam! You're handed the keys to manage a $100 million portfolio. That's the real-deal opportunity Natixis Investment Managers is dangling with its seventh Students Challenge. Diving Into the Nuts and Bolts Listen up, kids. Applications are open...

Continue Reading
NACCO Navigates Strong 2026 Q3, Faces Solar Cost Hurdles

Updated Category News Views 34

Rolling With NACCO's Financial Punches Well, folks, when it rains, it pours—numbers that is. NACCO Industries just laid out their Q3 results for all to gawk at, and it's a mixed bag of triumphs and tussles. You got a gross profit of $11.8 million, a sweet 18% jump on the same quarter last year. Now, you're talking about revenue muscle, and there it is. Income before...

Continue Reading

Top 5 Most Recently Viewed Articles

Vantiva Launches Cutting-Edge DOCSIS 4.0 FDD Cable Modem

Updated Category News Views 825

Vantiva Unveils Game-Changing DOCSIS 4.0 FDD Modem Vantiva, a prominent name in technology solutions, has introduced the Marlin Xe (CXA500Z), the first commercially available DOCSIS 4.0 Frequency Division Duplex (FDD) Cable Modem. This groundbreaking product is designed to allow service providers to deliver outstanding data speeds that rival the performance of...

Continue Reading
AST Welcomes Jacob Stephen as New Chief Operating Officer

Updated Category News Views 194

AST Welcomes Jacob Stephen as Chief Operating Officer Stephen to lead company-wide execution, strengthening AST's Executive Leadership Team AST is thrilled to announce that Jacob Stephen will be joining the AST Team as Chief Operating Officer at the drug product equipment manufacturing company headquartered in Tacoma. Jacob joins from IPS, where he excelled as Head of...

Continue Reading
Celebrating Bravery: Broward Sheriff's Heroes Recognized

Updated Category News Views 244

Ceremony Highlights Bravery and Dedication The Broward Sheriff's Advisory Council recently hosted a remarkable event dedicated to honoring the exceptional bravery and commitment of first responders in the community. This annual Tribute to Bravery ceremony took place at a beautiful venue by the beach, bringing together heroes and supporters alike. Acknowledging Local...

Continue Reading
Insight into Recent Riksbank Government Bond Auctions

Updated Category News Views 194

Overview of Riksbank Auctions for Government Bonds The Riksbank, Sweden's central bank, frequently holds auctions for government bonds as a way to manage monetary policy and influence the economy. These auctions are significant for investors, economists, and financial analysts who closely monitor the outcomes, as they provide insights into market sentiment and interest...

Continue Reading
Innovative Approaches in Neuroblastoma Treatment by Y-mAbs

Updated Category News Views 235

Y-mAbs Shares New Developments in Neuroblastoma Treatment Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB), a leading biopharmaceutical company dedicated to advancing cancer therapies, has announced exciting new research focused on treating neuroblastoma through innovative technologies. Recent clinical and preclinical findings related to naxitamab and the GD2-SADA platform were...

Continue Reading